P-PSMA-101 CAR-T cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).”In the company’s words, NCT04249947 on ClinicalTrials.gov
- Tested for
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male and 9 more
- Main trialPhase 1
- “An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.”In the company’s words, NCT04249947 on ClinicalTrials.gov
Other drugs for Prostatic Neoplasms, Castration-Resistant
- PasritamigJohnson & Johnson (Janssen) · Phase 3
- JNJ-87189401Johnson & Johnson (Janssen) · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- AAA617Novartis · Phase 2
- JSB462Novartis · Phase 2
- GedatolisibCelcuity Inc · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 30 Sep 2024 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026